ArticleBioMed research international2026
Serum Concentration of CRIPTO-1 in Pregnancies Complicated by Placenta Accreta Spectrum.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Concentration of CRIPTO-1 in Pregnancies Complicated by Placenta Accreta Spectrum.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo compare maternal serum CRIPTO-1 concentrations in pregnancies complicated by placenta accreta spectrum (PAS) with those complicated by placenta previa (PP).
methodsWe conducted a prospective, cross-sectional, comparative study at a tertiary center in São Paulo, Brazil (August 2022-May 2025). Singleton pregnancies with ultrasound-confirmed PP were included and classified as either PP without accreta or PAS (accreta/increta/percreta) according to standardized imaging criteria and, when applicable, surgical/histopathological confirmation. Maternal venous blood was collected predelivery, and serum CRIPTO-1 concentrations were measured using ELISA (Human CRIPTO SimpleStep ELISA Kit, Abcam). Primary analyses used nonparametric tests for continuous variables and Fisher's exact test for categorical variables. The study was approved by the Research Ethics Committee of the University of São Paulo (CAAE 58202122.8.0000.0065; CAAE 55121422.3.0000.0068).
resultsForty-three participants were analyzed (PP = 18; PAS = 25). Median serum CRIPTO-1 did not differ significantly between groups (PP: 0.013 pg/mL, IQR: 0.001-0.067 vs. PAS: 0.079 pg/mL, IQR: 0.005-0.360; p = 0.156). PAS was associated with greater blood loss (median 2240 vs. 568 mL; p < 0.001), higher transfusion rate (88.0% vs. 16.7%; p < 0.001), more ICU admissions (68.0% vs. 16.7%; p = 0.002), longer ICU and hospital stays (both p < 0.01), and higher hysterectomy rates (84.0% vs. 5.6%; p < 0.001).
conclusionsPredelivery serum CRIPTO-1 did not discriminate PAS from PP, possibly reflecting physiological variability at delivery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.